Ezetimibe | hsa00480 | Glutathione metabolism | 3.02E-02 | 1 | P48506 | GCLC | More | |
Ezetimibe | hsa00630 | Glyoxylate and dicarboxylate metabolism | 3.90E-04 | 3 | P40925, P40926, P15104 | MDH1, MDH2, GLUL | More | |
Ezetimibe | hsa01523 | Antifolate resistance | 3.80E-02 | 2 | Q92820, P04818 | GGH, TYMS | More | |
Ezetimibe | hsa02010 | ABC transporters | 3.76E-02 | 1 | Q99758 | ABCA3 | More | |
Ezetimibe | hsa03018 | RNA degradation | 3.02E-02 | 1 | Q13901 | C1D | More | |
Ezetimibe | hsa03040 | Spliceosome | 1.29E-03 | 9 | O60508, P17844, P08579, P51991, P61978, Q07955, Q01130, P11142, Q9Y2W2 | CDC40, DDX5, SNRPB2, HNRPA3, HNRPK, SFRS1, SFRS2, HSPA8, WBP11 | More | |
Ezetimibe | hsa04014 | Ras signaling pathway | 2.54E-02 | 5 | P42338, P20827, P49767, Q13009, P50151 | PIK3CB, EFNA1, VEGFC, TIAM1, GNG10 | More | |
Ezetimibe | hsa04071 | Sphingolipid signaling pathway | 1.94E-02 | 6 | Q9H228, P01375, Q13362, Q9BX95, P10415, Q9UQC2 | EDG8, TNF, PPP2R5C, SGPP1, BCL2, GAB2 | More | |
Ezetimibe | hsa04110 | Cell cycle | 6.80E-03 | 6 | P06493, O75293, P30304, P33981, P42773, P01106 | CDK1, GADD45B, CDC25A, TTK, CDKN2C, MYC | More | |
Ezetimibe | hsa04141 | Protein processing in endoplasmic reticulum | 1.91E-03 | 6 | P18848, Q15437, Q99941, P11142, P07900, Q9NR31 | ATF4, SEC23B, CREBL1, HSPA8, HSP90AA1, SAR1A | More | |
Ezetimibe | hsa04151 | PI3K-Akt signaling pathway | 1.69E-04 | 15 | P62753, P42338, P43657, P27348, P20827, P49767, P07900, P50151, O15335, Q13751, P22105, P14784, Q99941, P18848, O00141 | RPS6, PIK3CB, P2RY5, YWHAQ, EFNA1, VEGFC, HSP90AA1, GNG10, CHAD, LAMB3, TNXB, IL2RB, CREBL1, ATF4, SGK | More | |
Ezetimibe | hsa04211 | Longevity regulating pathway | 2.72E-02 | 3 | P51828, Q99941, P18848 | ADCY7, CREBL1, ATF4 | More | |
Ezetimibe | hsa04216 | Ferroptosis | 4.50E-02 | 1 | P48506 | GCLC | More | |
Ezetimibe | hsa04218 | Cellular senescence | 4.79E-02 | 4 | P01106, O75293, P30304, P06493 | MYC, GADD45B, CDC25A, CDK1 | More | |
Ezetimibe | hsa04261 | Adrenergic signaling in cardiomyocytes | 1.46E-02 | 4 | P51828, Q99941, P18848, Q13557 | ADCY7, CREBL1, ATF4, CAMK2D | More | |
Ezetimibe | hsa04340 | Hedgehog signaling pathway | 1.80E-02 | 4 | P49841, P22694, Q13635, P10415 | GSK3B, PRKACB, PTCH1, BCL2 | More | |
Ezetimibe | hsa04640 | Hematopoietic cell lineage | 3.69E-02 | 4 | P21926, P07766, P01730, P09564 | CD9, CD3E, CD4, CD7 | More | |
Ezetimibe | hsa04662 | B cell receptor signaling pathway | 9.78E-04 | 5 | P42338, P60033, P07948, P21854, Q8N149 | PIK3CB, CD81, LYN, CD72, LILRA2 | More | |
Ezetimibe | hsa04664 | Fc epsilon RI signaling pathway | 1.82E-02 | 3 | P42338, P07948, P09917 | PIK3CB, LYN, ALOX5 | More | |
Ezetimibe | hsa04714 | Thermogenesis | 3.31E-02 | 4 | P51828, P62753, P12074, O15239 | ADCY7, RPS6, COX6A1, NDUFA1 | More | |
Ezetimibe | hsa04724 | Glutamatergic synapse | 3.24E-02 | 3 | P43003, P50151, P15104 | SLC1A3, GNG10, GLUL | More | |
Ezetimibe | hsa04725 | Cholinergic synapse | 2.17E-02 | 3 | P51828, P18848, Q13557 | ADCY7, ATF4, CAMK2D | More | |
Ezetimibe | hsa04728 | Dopaminergic synapse | 4.78E-02 | 3 | Q99941, P18848, Q13557 | CREBL1, ATF4, CAMK2D | More | |
Ezetimibe | hsa04911 | Insulin secretion | 4.03E-04 | 4 | P51828, Q99941, P18848, Q13557 | ADCY7, CREBL1, ATF4, CAMK2D | More | |
Ezetimibe | hsa04912 | GnRH signaling pathway | 2.17E-02 | 3 | P51828, P18848, Q13557 | ADCY7, ATF4, CAMK2D | More | |
Ezetimibe | hsa04915 | Estrogen signaling pathway | 2.75E-03 | 5 | Q99941, P18848, P51828, P07900, P11142 | CREBL1, ATF4, ADCY7, HSP90AA1, HSPA8 | More | |
Ezetimibe | hsa04918 | Thyroid hormone synthesis | 1.69E-03 | 4 | P51828, Q99941, P18848, P02768 | ADCY7, CREBL1, ATF4, ALB | More | |
Ezetimibe | hsa04924 | Renin secretion | 3.64E-02 | 3 | P22694, P07550, Q14643 | PRKACB, ADRB2, ITPR1 | More | |
Ezetimibe | hsa04925 | Aldosterone synthesis and secretion | 1.69E-03 | 4 | Q99941, P18848, P51828, Q13557 | CREBL1, ATF4, ADCY7, CAMK2D | More | |
Ezetimibe | hsa04926 | Relaxin signaling pathway | 3.34E-02 | 3 | Q99941, P18848, P51828 | CREBL1, ATF4, ADCY7 | More | |
Ezetimibe | hsa04927 | Cortisol synthesis and secretion | 4.16E-03 | 3 | Q99941, P18848, P51828 | CREBL1, ATF4, ADCY7 | More | |
Ezetimibe | hsa04928 | Parathyroid hormone synthesis, secretion and action | 2.17E-02 | 3 | P51828, Q99941, P18848 | ADCY7, CREBL1, ATF4 | More | |
Ezetimibe | hsa04934 | Cushing syndrome | 1.12E-03 | 4 | Q99941, P18848, P51828, Q13557 | CREBL1, ATF4, ADCY7, CAMK2D | More | |
Ezetimibe | hsa04935 | Growth hormone synthesis, secretion and action | 2.72E-02 | 3 | P51828, Q99941, P18848 | ADCY7, CREBL1, ATF4 | More | |
Ezetimibe | hsa05030 | Cocaine addiction | 4.87E-02 | 2 | Q99941, P18848 | CREBL1, ATF4 | More | |
Ezetimibe | hsa05031 | Amphetamine addiction | 6.41E-03 | 3 | Q13557, Q99941, P18848 | CAMK2D, CREBL1, ATF4 | More | |
Ezetimibe | hsa05144 | Malaria | 4.92E-02 | 4 | O60603, P01375, P35443, P26718 | TLR2, TNF, THBS4, KLRK1 | More | |
Ezetimibe | hsa05161 | Hepatitis B | 3.34E-02 | 3 | Q99941, P18848, P27348 | CREBL1, ATF4, YWHAQ | More | |
Ezetimibe | hsa05203 | Viral carcinogenesis | 1.46E-02 | 4 | Q99941, P18848, P27348, P61978 | CREBL1, ATF4, YWHAQ, HNRPK | More | |
Ezetimibe | hsa05216 | Thyroid cancer | 3.80E-02 | 2 | P01106, O75293 | MYC, GADD45B | More | |
Ezetimibe | hsa05223 | Non-small cell lung cancer | 1.39E-02 | 3 | P10826, Q9HC35, O75293 | RARB, EML4, GADD45B | More | |
Ezetimibe | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 1.09E-02 | 4 | P07766, P06239, Q9HC35, P01730 | CD3E, LCK, EML4, CD4 | More | |
Ezetimibe | hsa05321 | Inflammatory bowel disease | 4.92E-02 | 4 | O60603, P01375, Q14765, Q9UL17 | TLR2, TNF, STAT4, TBX21 | More | |
Ezetimibe | hsa05332 | Graft-versus-host disease | 1.80E-02 | 4 | P10747, P01375, P26715, Q13241 | CD28, TNF, KLRC1, KLRD1 | More | |
Ezetimibe | hsa05340 | Primary immunodeficiency | 1.28E-03 | 4 | P01730, P11912, P07766, P06239 | CD4, CD79A, CD3E, LCK | More | |